首页> 外文期刊>Journal of drug targeting >PDK2 induces cisplatin-resistance in lung adenocarcinoma via transcriptional regulation of CNNM3
【24h】

PDK2 induces cisplatin-resistance in lung adenocarcinoma via transcriptional regulation of CNNM3

机译:PDK2通过CNM3的转录调节诱导肺腺癌中的顺铂抗性

获取原文
获取原文并翻译 | 示例
           

摘要

Recurrence of lung adenocarcinoma has become one of the most frequent causes of major cancer incidence and mortality worldwide according to its frequently gained resistance to chemotherapies. In this study, we identified a poorly-studied kinase pyruvate dehydrogenase kinase isoform 2 (PDK2) as the most up-regulated kinase encoding gene in Cisplatin resistant lung adenocarcinoma. Additionally, PDK2-dependent Cisplatin-resistance promotes tumour growth of lung adenocarcinoma both in vitro and in vivo. Clinically, PDK2 expression was up-regulated in lung adenocarcinoma and was correlated to the poor prognosis of lung cancer patients. Mechanically, PDK2 promoted cell growth and Cisplatin-resistance of lung adenocarcinoma via transcriptional regulation of cyclin and CBS domain divalent metal cation transport mediator 3 (CNNM3), indicating that PDK2-CNNM3 signalling axis could be a potential therapeutic target for Cisplatin-resistant lung adenocarcinoma.
机译:肺腺癌的复发已成为根据其经常对化学疗法的抗性的主要癌症发病率和死亡率最常见的原因之一。 在该研究中,我们将一种良好研究的激酶丙酮酸脱氢酶激酶同种型2(PDK2)作为顺铂抗肺腺癌中最上调的激酶编码基因。 另外,PDK2依赖性顺铂抵抗促进体外和体内肺腺癌的肿瘤生长。 临床上,PDK2表达在肺腺癌中上调,与肺癌患者的预后不良相关。 机械地,PDK2通过细胞周期蛋白和CNS结构域二价金属阳离子输送介体3(CNNM3)的转录调节促进肺腺癌的细胞生长和顺铂抗性,表明PDK2-CNM3信号轴可以是顺铂抗肺腺癌的潜在治疗靶标 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号